**Title:** Predictors and risk factors of short-term and long-term outcomes among women with gestational diabetes mellitus (GDM) and their offspring: Moving toward precision prognosis?

**Authors:** Zhila Semnani-Azad<sup>1</sup>, Romy Gaillard<sup>2</sup>, Alice E Hughes<sup>3</sup>, Kristen E. Boyle<sup>4</sup>, Deirdre K. Tobias<sup>1,5</sup>, Wei Perng<sup>6</sup>, as part of ADA/EASD PMDI

<sup>1</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup> Department of Pediatrics, Erasmus Medical Center, Rotterdam, Netherlands

<sup>3</sup> Faculty of Health and Life Sciences, University of Exeter Medical School, Exeter, United Kingdom

<sup>4</sup> Department of Pediatrics and the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

<sup>5</sup> Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>6</sup> Department of Epidemiology and the Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

# **Correspondence**:

Zhila Semnani-Azad, PhD

Department of Nutrition, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115. **T:** (617) 495-1000. **E-mail:** <u>zsemnaniazad@hsph.harvard.edu</u>

**Abbreviations**: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; MetS – metabolic syndrome; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes

# Funding:

Zhila Semnani-Azad is funded by Canadian Institutes of Health Research (CIHR) Fellowship.

*Romy Gaillard* is funded by the Dutch Diabetes Foundation (grant number 2017.81.002), the Netherlands Organization for Health Research and Development (NWO, ZonMw, grant number 543003109; NWO, ZonMw VIDI 09150172110034) and from the European Union's Horizon 2020 research and innovation programme under the ERA-NET Cofund action (no 727565), EndObesity, ZonMW the Netherlands (no. 529051026).

*Alice Hughes* is funded the Wellcome Trust GW4-Clinical Academic PhD Fellowship [WT203918].

Kristen Boyle is funded by R01DK117168.

Deirdre K. Tobias is funded by ADA-1-19-JDF-115.

*Wei Perng* is funded by American Diabetes Association (ADA)-7-22-ICTSPM-08 and National Institutes of Health (NIH) U01 DK134981.

**Conflict of interest/disclosure statement**: The funders played no role in the design, methodology, or interpretation of results of this work.

## 1 ABSTRACT

2 As part of the American Diabetes Association Precision Medicine in Diabetes Initiative 3 (PMDI) – a partnership with the European Association for the Study of Diabetes (EASD) – this systematic review is part of a comprehensive evidence evaluation in support of the 2<sup>nd</sup> 4 5 International Consensus Report on Precision Diabetes Medicine. Here, we sought to synthesize evidence from empirical research papers published through September 1<sup>st</sup>, 2021 to evaluate and 6 7 identify prognostic conditions, risk factors, and biomarkers among women and children affected 8 by gestational diabetes mellitus (GDM), focusing on clinical endpoints of cardiovascular disease 9 (CVD) and type 2 diabetes (T2D) among women with a history of GDM; and adiposity and 10 cardiometabolic profile among offspring exposed to GDM in utero. We identified a total of 107 11 observational studies and 12 randomized controlled trials testing the effect of pharmaceutical 12 and/or lifestyle interventions. Broadly, current literature indicates that greater GDM severity, 13 higher maternal body mass index, belonging to racial/ethnic minority group; and unhealthy 14 lifestyle behaviors would predict a woman's risk of incident T2D and CVD, and an unfavorable 15 cardiometabolic profile among offspring. However, the level of evidence is low (Level 4 16 according to the Diabetes Canada 2018 Clinical Practice Guidelines for diabetes prognosis) 17 largely because most studies leveraged retrospective data from large registries that are vulnerable 18 to residual confounding and reverse causation bias; and prospective cohort studies that may 19 suffer selection and attrition bias. Moreover, for the offspring outcomes, we identified a 20 relatively small body of literature on prognostic factors indicative of future adiposity and 21 cardiometabolic risk. Future high-quality prospective cohort studies in diverse populations with 22 granular data collection on prognostic factors, clinical and subclinical outcomes, high fidelity of 23 follow-up, and appropriate analytical approaches to deal with structural biases are warranted.

2

## 24 **1. INTRODUCTION**

Gestational diabetes mellitus (GDM) is the most common metabolic disorder of 25 pregnancy, affecting 6-12% of pregnancies globally<sup>1,2</sup>. A diagnosis of GDM indicates a state of 26 27 maternal hyperglycemia due to insufficient insulin secretion and/or insulin resistance that is 28 associated not only with risk of acute pregnancy complications, but also carries implications for 29 the long-term health of the mother and offspring. For instance, in women, GDM is associated 30 with up to 70% higher cumulative incidence of type 2 diabetes (T2D) following the index pregnancy<sup>3</sup> and two-fold greater risk of cardiovascular disease (CVD) than gravidas without 31 GDM<sup>4</sup>. Additionally, offspring exposed to GDM *in utero* have higher adiposity and a worse 32 metabolic profile than their unexposed counterparts <sup>5</sup>. The wide-ranging and intergenerational 33 34 sequelae of GDM-affected pregnancies emphasize the importance of characterizing not only the 35 short- and long-term consequences of this common pregnancy complication, but also, early 36 bellwethers of such consequences to facilitate preventive intervention of such comorbidities and 37 complications – a concept known as disease *prognosis*.

Recent technological advancements have improved the capacity to comprehensively assess physiology. In turn, these developments facilitated the ability to harness metabolic heterogeneity – the phenomenon of interest to precision medicine <sup>6</sup>, by which similar exposures and risk factors yield differential health sequelae across individuals. In the context of GDM prognosis, this effort requires the identification of prognostic conditions and biomarkers among women with a history of GDM and/or their children who were exposed to GDM *in utero* that may serve as both causal and non-causal indicators of future health risks.

45 Recognizing the relevance of metabolic heterogeneity in accurate and precise assessment
46 of metabolic disease prediction, diagnosis, treatment, and prognosis, the *Precision Medicine in*

3

*Diabetes Initiative* (PMDI) was established in 2018 by the American Diabetes Association (ADA) in partnership with the European Association for the Study of Diabetes (EASD). The ADA/EASD PMDI includes global thought leaders in precision diabetes medicine who are working to address the burgeoning need for better diabetes prevention and care through precision medicine <sup>7</sup>. This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a comprehensive evidence evaluation in support of the 2<sup>nd</sup> International Consensus Report on Precision Diabetes Medicine <sup>1</sup>.

Here, we synthesize evidence from empirical research papers published through September 1<sup>st</sup>, 2021 to evaluate and identify prognostic conditions, risk factors, and biomarkers among women and children affected by GDM pregnancies, focusing on clinical endpoints of CVD and T2D among women with a history of GDM; and adiposity and cardiometabolic profile among offspring exposed to GDM *in utero*.

## 59 **2. METHODS**

### 60 2.1. Systematic review protocol development

61 We developed a systematic review protocol to comprehensively include and evaluate 62 individual research studies reporting on risk factors for long-term clinical outcomes in women 63 with GDM and a range of cardiometabolic health and anthropometric outcomes in GDM-64 exposed offspring. Our strategy aimed to identify two broad categories of empirical studies: (1) 65 populations of women with a history of prior GDM that investigated additional exposures or risk factors for incident postpartum T2D or CVD; (2) populations comprising offspring exposed to 66 67 GDM in utero. Studies including pregnancies unaffected by GDM were eligible only if results 68 among GDM subgroups were reported.

69 Prognostic factors of interest - hereafter also referred to as "exposures" - included 70 sociodemographic and environmental factors, lifestyle and behavioral characteristics, traditional 71 clinical traits, and novel 'omics biomarkers. We considered these prognostic factors during the 72 perinatal/postpartum periods and across the lifecourse for both the mothers and offspring. 73 Maternal outcomes of interest were incident T2D or CVD, including study-specific composites 74 of clinical cardiovascular events, non-fatal and fatal myocardial infarction or stroke, and chronic 75 kidney disease (CKD). For offspring, we were interested in outcomes reported 12 weeks of age 76 and older, and limited to anthropometrics, glycemic and cardiometabolic traits or biomarkers, 77 and incident metabolic syndrome (MetS), T2D, or CVD.

#### 78 **2.2. Data sources, search strategy, and screening criteria**

We published our search strategy and systematic review protocol to PROSPERO CRD42021276094<sup>8</sup>. We developed search terms for Medline EMBASE, and Cochrane CENTRAL (**Supplemental Table 1**) for eligible citations published in English language from

January 1<sup>st</sup>, 1990 through September 30<sup>th</sup>, 2021. References of accepted manuscripts and relevant 82 83 systematic reviews published within the past 2 years were screened to identify additional 84 citations. We included prospective and retrospective observational studies identifying factors 85 with incident outcomes of interest in women or offspring exposed to GDM. We excluded cross-86 sectional analyses among populations with prevalent disease outcomes or traits. While studies 87 could include non-GDM exposed pregnancies, those without subgroup findings exclusively 88 among GDM pregnancies were excluded. We also included interventions prospectively 89 comparing effects of a treatment assignment on the outcome. Exclusion criteria comprised 90 studies with outcomes <12 weeks postpartum, maternal studies reporting only intermediate 91 phenotypes, glycemic traits, or cardiometabolic biomarkers, and studies in offspring that only 92 assessed endpoints outside of the cardiometabolic outcomes of interest (e.g., neurodevelopment, 93 allergic disease). Using these, two independent reviewers conducted screening at the title abstract 94 level. For accepted citations, two independent reviewers implemented screening of the full 95 manuscripts. Conflicts at all screening stages were resolved by a third reviewer. All screening 96 was conducted in the Covidence online systematic review tracking platform.

97

### 2.3. Data extraction and synthesis of results

We developed and piloted a data extraction template for eligible manuscripts. Data included manuscript information, study level details and design, population enrollment and characteristics, exposure and outcome ascertainment and diagnosis criteria, follow-up time of outcome assessment since index GDM pregnancy and other pertinent details. We indicated the population in which outcomes were assessed (e.g., maternal, offspring, or both), and recorded the exposures that were investigated in four broad categories: (i) social/environmental/genetics

factors across the life course; (ii) all factors in perinatal/postpartum window; (iii) long-term
 maternal exposures; and (iv) long-term offspring exposures.

## 106 **2.4. Quality assessment (risk of bias) and synthesis**

107 We assessed the quality of each study using the Joanna Briggs Institute's (JBI) critical appraisal tools for cohort studies and randomized controlled trials (RCTs)<sup>9</sup>. For cohort studies, 108 109 we assessed quality based on 11 items which evaluated population recruitment, exposure and 110 outcome ascertainment, confounding, statistical methodology, and follow-up. For the RCTs, the 111 JBI criteria evaluated 13 items which assessed selection and allocation, intervention, 112 administration, outcome ascertainment, follow-up, and statistical analysis. Each JBI item was 113 categorized as 'Yes', 'No', 'Unclear' or 'Not applicable' following the described guidelines. 114 Any uncertainty in assessment was further discussed by the full research team.

### 115 **2.5.** Overall evidence certainty assessment and synthesis

The certainty of evidence was determined using the Diabetes Canada 2018 Clinical Practice Guidelines for studies <sup>10</sup>. Levels were based on study design and criteria focused on inception cohort of patients presenting GDM but without outcomes of interest, inclusion/exclusion reproducibility, follow-up of at least 80% of participants, adjustment for confounding factors, and reproducible outcome measures. Scoring ranged from level 1 to 4, with Level 1 indicating the highest certainty of evidence and Level 4 indicating the lowest certainty of evidence. Details on the criteria and guidelines are presented in **Supplemental Table 2**.

### 123 **3. RESULTS**

Figure 1 displays results of the systematic search and article inclusion process. Of the 8,141 studies identified, five were excluded due to duplication. Another 7,770 were excluded following title and abstract review. The remaining 341 studies were reviewed in full. A total of 119 studies met the inclusion criteria for this review.

**Table 1** outlines the summary of studies included in this systematic review. Of the 119 studies identified, 107 were observational studies and 12 were RCTs. Of the observational studies, 57 studies <sup>2-55</sup> reported on maternal outcomes and 51 studies <sup>56-106</sup> reported on offspring outcomes. Of the RCTs, three evaluated maternal outcomes <sup>107-109</sup> and nine assessed offspring outcomes <sup>61,91,110-116</sup>. Studies included data from primarily from Caucasian ethnicities with publications mainly from North American (n = 25) and European (n = 39) countries. The sample sizes of the eligible studies ranged from 26 to 23 302.

135

#### 136 **3.1. Maternal outcomes**

#### 137 **3.1.1. Maternal type 2 diabetes**

Fifty-one observational studies <sup>11-61</sup> (**Table 2**) and three RCTs <sup>62-64</sup> (**Table 3**) assessed 138 139 socio-demographic, lifestyle, clinical and pregnancy characteristics associated with the risk of 140 T2D among GDM women. The most commonly-studied characteristics were maternal BMI and 141 GDM severity. Twenty-four observational studies showed that a higher BMI, measured prior to 142 pregnancy, pregnancy or during the lifecourse was associated with a higher risk of T2D. Two 143 observational studies further showed that a higher weight gain in the postpartum period also 144 increased the risk of T2D. Fifteen studies assessed the role of GDM severity on the risk of 145 developing T2D and showed that more severe GDM, measured by either clinical markers or need

146 for insulin, was associated with a higher risk of developing T2D (**Table 2**). One study was a 147 RCT; all other studies were observational. Fewer studies explored the role of lifestyle/behavioral, 148 pregnancy, and clinical characteristics. Six studies explored the role of race/ethnicity in risk of 149 T2D, two of which showed no significant associations (**Table 2**). Four studies suggested that the 150 risk was higher among women with non-European ancestry. With regards to pregnancy 151 characteristics, findings were inconsistent with three of six observational studies reporting an 152 association of a complicated pregnancy with higher risk of T2D. The pregnancy complications 153 assessed varied across reports. Six studies explored the role of parity, of which three showed 154 that higher parity was associated with a higher risk of T2D. Four observational studies showed 155 that breastfeeding was associated with reduced risk of developing T2D in later life. Three 156 studies including one RCT focused on various healthy dietary patterns and the risk of T2D 157 among GDM women but showed inconsistent results. Seven small studies used novel clinical 158 biomarkers, including metabolomics, lipidomics, and diabetes auto-antibodies, and found 159 positive associations with T2D.

160 **3.1.2. Maternal cardiovascular diseases** 

Six observational studies <sup>11,31,65-68</sup> (**Table 4**) explored the role of sociodemographic, lifestyle, and pregnancy characteristics in future risk of CVD among women with GDM. Three studies <sup>11,66,67</sup> identified maternal BMI, before or during pregnancy, as a determinant of CVD risk, in which overweight and obese women with GDM have a higher risk of future CVD as compared to normal weight women with GDM. A study further showed that a healthy lifestyle – i.e., healthy diet, physical activity and non-smoking - was associated with a lower risk of CVD among women with GDM <sup>66</sup>. Two studies showed that pregnancy complications, including

gestational hypertension <sup>68</sup> and stillbirth <sup>31</sup>, predicted risk of CVD among women of GDM. No
significant effect modification was found by family history or chronic hypertension.

#### 170 **3.1.3.** Quality of studies conducted and certainty of evidence in maternal populations

The quality of studies reviewed herein for prognostic factors indicative of risk of T2D or CVD is low and the overall certainty of evidence ranked between Levels 3 and 4 according to the Diabetes Canada 2018 Clinical Practice Guidelines <sup>10</sup>. Most current literature were based on retrospective studies leveraging registry data and observational cohort studies, both of which are vulnerable to bias and an inability to attribute causation to prognostic factors due to residual confounding, reverse causation bias by pre-existing conditions, and other characteristics around

177 time of pregnancy and GDM diagnoses.

## 178 **3.2. Offspring outcomes**

## 179 **3.2.1.** Anthropometry and body composition

In comparison to the relatively large maternal literature, fewer studies have focused on 180 181 prognostic factors associated with suboptimal offspring body composition among those exposed to GDM *in utero*. Forty-three observational studies <sup>56-98</sup> (Table 5) and four RCTs <sup>110,113,115,116</sup> 182 183 (Table 6) examined associations of sociodemographic, lifestyle, clinical and pregnancy 184 characteristics associated with anthropometric outcomes offspring of GDM women. The most 185 commonly-studied characteristics were maternal BMI, GDM severity, breastfeeding status, and 186 birthweight, and were compared to anthropometric outcomes, specifically BMI and risk of 187 overweight. Five observational studies showed that a higher maternal pre-pregnancy BMI was 188 associated with an adverse body composition in the offspring, reflected by a higher BMI, waist 189 circumference, or body fat mass, and a higher risk of overweight or obesity. Twelve studies 190 assessed the associations of maternal GDM severity, measured by either clinical markers or need

191 for insulin, with offspring body composition. Most of eight observational studies, only three 192 indicated that more severe maternal GDM is associated with a higher offspring BMI and 193 overweight risk. All four identified RCTs evaluated GDM severity and overall showed no 194 significant association with offspring anthropometry or body composition. Four observational 195 studies showed that a higher size at birth is associated with higher BMI and risk of overweight in 196 GDM offspring, but four studies reported no significant associations. Two studies showed that 197 offspring that a higher size at birth but with exposure to breastfeeding were associated with 198 lower offspring BMI and reduced risk of overweight or obesity. With regards to breastfeeding 199 status, only observational studies showed that exclusive breastfeeding and a longer duration of 200 breastfeeding were associated with a lower offspring BMI and lower risk of overweight or 201 obesity. Only four small studies used novel clinical biomarkers, including metabolomics in cord 202 blood and gene expression in muscle and adipose tissue and showed variable associations with 203 body composition. Furthermore, four independent studies using data from the Danish National Birth Cohort indicated that maternal diet consisting of fatty fish <sup>77</sup>, refined grain <sup>98</sup>, and sugar-204 sweetened beverage intake <sup>97</sup> were associated with higher offspring BMI, while protein intake 205 did not show significant impact on offspring abdominal fat  $^{76}$ . 206

207 **3.2.2. Cardiometabolic profile** 

Only a few studies explored risk factors for adverse cardiometabolic outcomes in GDM offspring. These studies focused on blood pressure, lipids, and glycemic markers in the offspring separately or on metabolic syndrome like phenotypes, integrating several of these components and offspring anthropometric measures. Fourteen observational studies <sup>69-8711</sup> (**Table 7**) and seven RCTs<sup>82-88</sup> (**Table 8**) were identified. Four observational studies assessed associations of different maternal dietary components including macronutrients or specific micronutrients, and

214 showed no consistent associations with offspring cardiometabolic outcomes. Several RCTs 215 compared diet vs insulin treatment of GDM and showed no significant associations with the 216 development of a metabolic syndrome like phenotype in the offspring. One RCT evaluating a 217 lifestyle intervention including exercise and diet counselling for treatment of GDM compared to 218 clinical care showed a higher risk of unfavorable metabolic outcomes in the offspring in the 219 intervention group. One observational study showed that breastfeeding was associated with a 220 lower risk of metabolic syndrome like phenotype in the offspring of GDM women, but one 221 observational study showed no consistent effects. Birthweight was the most commonly-studied 222 predictor of the offspring exposures. Two observational studies showed that a higher birthweight 223 in offspring of GDM women was associated with a higher risk of metabolic syndrome like 224 phenotype in offspring, whereas study showed association. one no

## **3.2.3.** Quality of studies and certainty of evidence conducted in offspring populations

226 At the individual study level, we identified low quality of evidence for prognostic factors 227 indicative of future adiposity and cardiometabolic risk among offspring exposed to GDM in 228 utero. As with the maternal literature, most studies focusing on offspring outcomes were based 229 on retrospective study designs leveraging registry data and observational cohort studies, both of 230 which can be fraught with residual confounding and reverse causation bias, as well as structural 231 biases like selection and attrition bias. Moreover, the literature of offspring outcomes remains 232 relatively scant and with potentially inadequate durations of follow-up for manifestation of 233 clinically-relevant cardiometabolic outcomes, though additional research is warranted. 234 Furthermore, the certainty of evidence for maternal and offspring exposures with cardiometabolic outcomes were scored Level 4 based on the Diabetes Canada guidelines.<sup>10</sup> 235

- 236 based several factors including limited studies, small sample sizes, heterogeneity of study
- 237 designs, and inadequate statistical methods.

#### **4. DISCUSSION**

#### **4.1. Summary**

This systematic review sought to identify prognostic risk factors during the perinatal period and across the lifecourse for maternal and offspring cardiovascular and metabolic outcomes among women and children affected by GDM pregnancies. We hypothesized that worse glycemic control at the time of GDM diagnosis (i.e., severity of GDM), older maternal age, belonging to racial/ethnic minority group; and unfavorable lifestyle behaviors would predict risk of full-blown type 2 diabetes (T2D) and cardiovascular disease (CVD) among women, and an unfavorable cardiometabolic profile among offspring.

247 The studies identified were primarily long-term retrospective and prospective studies. 248 The level of evidence for prognostic risk factors of maternal T2D and CVD and for offspring 249 cardiometabolic risk is low - i.e., Level 4 according to the Diabetes Canada 2018 Clinical Practice Guidelines for diabetes prognosis  $10^{10}$  – largely due to unmeasured confounding by 250 251 lifestyle behaviors, the possibility of reverse causation bias due to pre-existing chronic 252 conditions prior to or at the time of GDM diagnosis, and for offspring outcomes, the small body 253 of literature on prognostic factors indicative of future adiposity and cardiometabolic risk. In the 254 sections below, we synthesize general findings and comment further on quality of studies.

#### **4.2. Maternal outcomes**

#### 256 **4.2.1. Cardiovascular disease**

In line with a large literature demonstrating that women with a history of GDM are at higher risk CVD than their non-diabetic counterparts <sup>89,90</sup>, studies among women with a history of GDM indicated dose-response associations of GDM severity with these endpoints. Additionally, maternal pre-pregnancy or early pregnancy BMI was the most assessed prognostic

factor linked to future CVD risk. Additionally, prenatal smoking, stillbirth, and gestational hypertension were each associated with risk for CVD in women with a history of GDM, whereas chronic hypertension and family history of CVD were not. Given the paucity of available research on CVD risk in women with a history of GDM, and the low certainty of evidence assessment, this is a research area ripe for investigation.

266 **4.2.2. Type 2 diabetes** 

267 Among women with GDM, higher BMI at any time in relation to the index pregnancy – 268 i.e., pre-pregnancy, during the index pregnancy including gestational weight gain, and lifecourse 269 measures of weight – predicted higher risk of T2D later in life. GDM severity, typically 270 estimated by use of insulin or higher blood glucose values during the index pregnancy, was 271 consistently associated with higher risk of developing T2D. While few studies assessed race 272 and/or ethnicity as a prognostic risk factor, women of Asian or non-European descent with a history of GDM had higher risk of future T2D than White women <sup>24,30,50</sup>. Breastfeeding duration 273 274 and/or exclusivity was consistently associated with lower risk T2D risk following a GDM 275 diagnosis during pregnancy, though follow-up often ended <2 years postpartum – a timeframe 276 within which occult T2D incidence is relatively low. Longer duration follow-up is necessary to 277 better evaluate the benefits of breastfeeding on T2D risk. Other lifestyle factors of interest 278 included physical activity level during the perinatal and postpartum periods, as well as 279 compliance with a healthy diet (e.g., adherence to a Mediterranean or DASH-like dietary pattern; 280 the Healthy Eating Index score). However, observational findings with respect to these variables 281 were mixed and RCTs investigating the effects of dietary interventions yielded mixed results 62,64 282

Several studies have examined biomarkers associated with increased risk for T2D following GDM pregnancies, including glycemic control at the time of GDM diagnosis, lipids <sup>28</sup>, inflammatory biomarkers <sup>28</sup>, and novel biomarkers lipidomics <sup>23</sup> and metabolomics <sup>47</sup> biomarkers. While these findings align with the literature in other pregnant <sup>91</sup> and non-pregnant populations <sup>92</sup>, the low certainty of evidence from the studies and lack of replication/validation of findings prevent us from drawing firm conclusions regarding which factors may be the best predictors of future diabetes.

# 290 **4.2.3. Quality of maternal studies**

291 We ranked the quality of evidence for prognostic factors indicative of risk of T2D or CVD in women as Level 4 (low)<sup>10</sup>. Most empirical literature comes predominantly from large 292 293 health care registries that boast large sample sizes and decades of follow-up. However, they carry 294 high risk of bias in terms of identifying and interpretation specific prognostic characteristics as 295 causal risk factors due to residual confounding due to maternal lifestyle, pre-existing chronic 296 conditions, and other characteristics around time of pregnancy and GDM diagnoses. For 297 example, maternal hypertension status in pregnancy as a causal risk factor for T2D or CVD 298 could be explained in part by maternal BMI, diet quality, physical activity, smoking status, 299 socioeconomic factors, and more. In contrast, there are notable large prospective cohorts, 300 including the CARDIA study and the Nurses' Health Study II, which collected detailed 301 prospective information on the above-mentioned variables.

- 302 **4.3. Offspring outcomes**
- 303 **4.3.1.** Anthropometry and body composition

The most common measure of offspring anthropometry was BMI between 2 and 10 years after birth. In alignment with maternal outcomes, GDM severity and higher maternal pre-

306 pregnancy BMI were associated with higher offspring adiposity, as indicated by 307 overweight/obesity status. Yet, interpretation of these findings should be tempered those of intervention studies showing that GDM treatment did not affect offspring anthropometrics <sup>82,85,93</sup>. 308 309 Similarly, RCTs testing the effects of pharmaceutical treatments (Metformin, insulin) and lifestyle interventions<sup>83</sup> to prevent GDM<sup>94,95</sup>. Other frequently studied perinatal predictors of 310 311 offspring adiposity included birth size and breastfeeding duration/exclusivity. Generally, higher 312 birthweight tended to be positively correlated with offspring BMI, though this association may be explained by the correlation between maternal and offspring BMI <sup>94</sup>. Some observational 313 314 studies showed a protective effect of breastfeeding on offspring childhood obesity risk, though 315 this finding was not consistent and we did not identify any RCTs to support this finding. While a few studies reported a modifying effect of offspring sex on future body composition (e.g., <sup>96-98</sup>), 316 317 the direction of association was not consistent.

318 4.3.2

#### 4.3.2. Cardiometabolic profile

Most studies that assessed offspring cardiometabolic profile were observational and focused on prognostic factors that occurred during the perinatal/postpartum period, though we identified a few RCTs that targeted maternal glycemic control during pregnancy via pharmaceutical treatments and/or lifestyle alterations.

Among observational studies, the most common prognostic factor was GDM severity  $^{86,99-101}$  at times assessed in conjunction with maternal BMI <sup>100</sup>. Although the magnitude of effects for GDM severity ranged across populations, greater severity was associated with worse glycemic control and an unfavorable cardiovascular profile in offspring. In addition to traditional biomarkers, one study identified hypothalamic activation as a determinant of BMI gain within the next year – a phenomenon that may mediate and/or modify the effect of GDM exposure *in*  *utero* <sup>102</sup>. As with the studies discussed above with respect to offspring anthropometry and body composition, RCTs to prevent GDM among high-risk women generally found minimal effects of the pharmaceutical and/or lifestyle interventions on offspring cardiometabolic profile, again suggesting that additional research is needed to better understand the pathophysiology of maternal GDM, to characterize relevant *in utero* programming pathways, and perhaps identify more specific and relevant offspring outcomes <sup>5</sup>.

## 335 **4.3.3. Quality of offspring studies**

336 As with the maternal studies, we categorized the literature on prognostic factors for 337 offspring outcomes as being of low quality (Level 4). The inconsistent observational findings in 338 conjunction with null results of RCTs targeting prevention of GDM among high-risk women 339 indicate the existence of residual confounding for observational studies, and in the cases of the 340 trials, the possibility that the interventions were developed with a suboptimal endpoint. 341 Specifically, many prenatal interventions among women at high risk of GDM were developed 342 with the goal of preventing macrosomia, which is a relatively crude indicator of developmental 343 overnutrition and offspring adiposity. Future work is needed to gain a better understanding of in 344 utero programming mechanisms that may link maternal GDM to offspring adiposity, as well as de novo interventions formulated to prevent neonatal adiposity assessed via gold standard 345 346 methods such as air displacement plethysmography or dual X-ray absorptiometry<sup>5</sup>.

#### 347 **5. STRENGTHS AND LIMITATIONS**

#### **5.1. Strengths and limitations of studies included in the systematic review**

A key strength of many studies included in this systematic review is the prospective study design, which enhances temporal and causal inference regarding prognostic capacity of the maternal and offspring characteristics and behaviors assessed in studies herein. Additional

352 strengths of some, but not all studies, include multi-ethnic study populations, which enhance 353 generalizability of findings; large sample sizes, which improves capacity to detect biologically 354 relevant associations; and use of gold standard assessments of the maternal and offspring 355 outcomes of interest.

Limitations include the low-grade quality of studies included in this review (residual 356 357 confounding, reverse causation bias, attrition and selection bias, inadequate duration of follow-358 up). Additionally, most studies were not designed to explore the long-term prognosis of GDM. 359 Accordingly, many studies comprise *post hoc* analyses that were likely underpowered to detect 360 smaller but biologically relevant effects of prognostic risk factors solely among mothers and/or 361 offspring exposed to GDM. Nota bene, when screening studies, we noted that a general 362 limitation of the literature on GDM prognostics in relation to offspring outcomes is assessment 363 of the prognostic variable(s) contemporaneously with outcome assessment. These shortcomings 364 resulted in high risk of bias and low quality of studies reviewed herein.

#### 365 **5.2.** Strengths and limitations of systematic review approach and methodology

Strengths of the methodology for this systematic review include implementation of at least two independent reviews across all phases of the extraction and assessment process, with an additional review by a third independent reviewer to resolve conflicts; and adherence to wellestablished assessments of research quality and assessments of bias. Limitations include the exclusively qualitative synthesis of results – a necessity given the relatively small number of studies identified; and as with all systematic reviews, the potential for our conclusions to be impacted by publication bias.

#### **373 6. FUTURE DIRECTIONS**

374 Given the low quality of evidence identified in this systematic review, there is need for 375 prospective cohort studies in diverse populations with granular data collection on prognostic risk 376 factors as well as clinical and subclinical outcomes; high fidelity of follow-up across the 377 lifecourse but, in particular, during sensitive windows of development during which there is 378 greater developmental plasticity to respond to external cues <sup>103</sup>; consideration of appropriate 379 adjustment covariates depending on the specific prognostic risk factor of interest (e.g., there is 380 discourse regarding whether maternal pre-pregnancy BMI should be included as a covariate in 381 models where GDM severity is the prognostic risk factors of interest given that these two variables likely share overlapping *in utero* programming pathways <sup>117,118</sup>); and appropriate causal 382 inference <sup>104</sup> and analytical approaches <sup>105</sup> to address structural biases that afflict observational 383 384 study designs.

As interest in the application of precision prognostics to improve health for women and children affected by GDM pregnancies grows, there remains a need to establish a foundational knowledge base regarding traditional prognostic factors which, in turn, will enhance our ability to identify novel prognostic biomarkers that improve risk stratification for unfavorable health outcomes among mother-offspring dyads affected by GDM.

# 390 ACKNOWLEDGEMENTS

391 The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was conducted, 392 has received the following support: The Covidence license was funded by Lund University 393 (Sweden) for which technical support was provided by Maria Björklund and Krister Aronsson 394 (Faculty of Medicine Library, Lund University, Sweden). Administrative support was provided 395 by Lund University (Malmö, Sweden), University of Chicago (IL, USA), and the American 396 Diabetes Association (Washington D.C., USA). The Novo Nordisk Foundation (Hellerup, 397 Denmark) provided grant support for in-person writing group meetings (PI: L Phillipson, 398 University of Chicago, IL). We also thank Marie-France Hivert for her valuable insights and 399 feedback on this work.

400

## 401 **REFERENCES**

- 402 1. Nolan JJ, Kahkoska AR, Semnani-Azad Z, et al. ADA/EASD Precision Medicine in
- 403 Diabetes Initiative: An International Perspective and Future Vision for Precision
- 404 Medicine in Diabetes. *Diabetes care*. 2022;45(2):261-266.
- 405 2. Gunderson EP, Lewis CE, Lin Y, et al. Lactation Duration and Progression to Diabetes in
- 406 Women Across the Childbearing Years: The 30-Year CARDIA Study. *JAMA internal*
- 407 *medicine*. 2018;178(3):328-337.
- 408 3. Vince K, Poljičanin T, Brkić M, Rodin U, Matijević R. Prevalence of diabetes five years
- 409 after having gestational diabetes during pregnancy Croatian national study. *Primary*
- 410 *care diabetes.* 2018;12(4):325-330.
- 411 4. Varner MW, Rice MM, Landon MB, et al. Pregnancies After the Diagnosis of Mild
- 412 Gestational Diabetes Mellitus and Risk of Cardiometabolic Disorders. *Obstetrics and*
- 413 *gynecology*. 2017;129(2):273-280.
- 414 5. Li W, Leng J, Liu H, et al. Nomograms for incident risk of post-partum type 2 diabetes in
- 415 Chinese women with prior gestational diabetes mellitus. *Clinical endocrinology*.
- 416 2019;90(3):417-424.
- 417 6. Liu H, Zhang C, Zhang S, et al. Prepregnancy body mass index and weight change on
- 418 postpartum diabetes risk among gestational diabetes women. *Obesity (Silver Spring, Md)*.
- 419 2014;22(6):1560-1567.
- 420 7. Li W, Zhang S, Liu H, et al. Different associations of diabetes with  $\beta$ -cell dysfunction and
- 421 insulin resistance among obese and nonobese Chinese women with prior gestational
- 422 diabetes mellitus. *Diabetes care*. 2014;37(9):2533-2539.

423	8.	Steinhart JR, Sugarman JR, Connell FA. Gestational diabetes is a herald of NIDDM in
424		Navajo women. High rate of abnormal glucose tolerance after GDM. Diabetes care.
425		1997;20(6):943-947.
426	9.	Hakkarainen H, Huopio H, Cederberg H, Voutilainen R, Heinonen S. Delivery of an LGA
427		infant and the maternal risk of diabetes: A prospective cohort study. Primary care
428		diabetes. 2018;12(4):364-370.
429	10.	Wang Y, Chen L, Horswell R, et al. Racial differences in the association between
430		gestational diabetes mellitus and risk of type 2 diabetes. Journal of women's health
431		(2002). 2012;21(6):628-633.
432	11.	Chodick G, Elchalal U, Sella T, et al. The risk of overt diabetes mellitus among women
433		with gestational diabetes: a population-based study. Diabetic medicine : a journal of the
434		British Diabetic Association. 2010;27(7):779-785.
435	12.	Lappas M, Mundra PA, Wong G, et al. The prediction of type 2 diabetes in women with
436		previous gestational diabetes mellitus using lipidomics. Diabetologia. 2015;58(7):1436-
437		1442.
438	13.	Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus:
439		clinical predictors and long-term risk of developing type 2 diabetes: a retrospective
440		cohort study using survival analysis. Diabetes care. 2007;30(4):878-883.
441	14.	Retnakaran R, Shah BR. Fetal Sex and the Natural History of Maternal Risk of Diabetes
442		During and After Pregnancy. The Journal of clinical endocrinology and metabolism.
443		2015;100(7):2574-2580.

444	15.	Kawasaki M, Arata N, Sakamoto N, et al. Risk factors during the early postpartum period
445		for type 2 diabetes mellitus in women with gestational diabetes. Endocrine journal.
446		2020;67(4):427-437.

- 16. Lin PC, Hung CH, Huang RD, Chan TF. Predictors of type 2 diabetes among Taiwanese
- 448 women with prior gestational diabetes mellitus. *Japan journal of nursing science : JJNS*.

449 2016;13(1):3-9.

450 17. Rivero K, Portal VL, Vieira M, Behle I. Prevalence of the impaired glucose metabolism

451 and its association with risk factors for coronary artery disease in women with gestational

452 diabetes. *Diabetes research and clinical practice*. 2008;79(3):433-437.

- 453 18. Akinci B, Celtik A, Genc S, et al. Evaluation of postpartum carbohydrate intolerance and
- 454 cardiovascular risk factors in women with gestational diabetes. *Gynecological*
- 455 endocrinology : the official journal of the International Society of Gynecological
- 456 *Endocrinology*. 2011;27(5):361-367.
- 457 19. Myers JE, Hasan X, Maresh MJ. Post-natal assessment of gestational diabetes: fasting
- 458 glucose or full glucose tolerance test? *Diabetic medicine : a journal of the British*
- 459 *Diabetic Association*. 2014;31(9):1133-1137.
- Pintaudi B, Lucisano G, Pellegrini F, et al. The long-term effects of stillbirth on women
  with and without gestational diabetes: a population-based cohort study. *Diabetologia*.
- 462 2015;58(1):67-74.
- 463 21. Eades CE, Styles M, Leese GP, Cheyne H, Evans JM. Progression from gestational
- 464 diabetes to type 2 diabetes in one region of Scotland: an observational follow-up study.
- 465 *BMC pregnancy and childbirth.* 2015;15:11.

466	22.	Kugishima Y, Yasuhi I, Yamashita H, et al. Risk factors associated with the development
467		of postpartum diabetes in Japanese women with gestational diabetes. BMC pregnancy
468		and childbirth. 2018;18(1):19.
469	23.	Tseng CH. Parental diabetes in Taiwanese diabetic women with and without previous

- 470 gestational diabetes. *European journal of clinical investigation*. 2008;38(8):555-561.
- 471 24. Bao W, Yeung E, Tobias DK, et al. Long-term risk of type 2 diabetes mellitus in relation
- 472 to BMI and weight change among women with a history of gestational diabetes mellitus:
  473 a prospective cohort study. *Diabetologia*. 2015;58(6):1212-1219.
- 474 25. Pirkola J, Pouta A, Bloigu A, et al. Prepregnancy overweight and gestational diabetes as
- determinants of subsequent diabetes and hypertension after 20-year follow-up. *The*

476 *Journal of clinical endocrinology and metabolism.* 2010;95(2):772-778.

477 26. Ley SH, Chavarro JE, Li M, et al. Lactation Duration and Long-term Risk for Incident

478 Type 2 Diabetes in Women With a History of Gestational Diabetes Mellitus. *Diabetes*479 *care*. 2020;43(4):793-798.

- 480 27. Tobias DK, Hu FB, Chavarro J, Rosner B, Mozaffarian D, Zhang C. Healthful dietary
- 481 patterns and type 2 diabetes mellitus risk among women with a history of gestational

482 diabetes mellitus. *Archives of internal medicine*. 2012;172(20):1566-1572.

- 483 28. Tobias DK, Clish C, Mora S, et al. Dietary Intakes and Circulating Concentrations of
- 484 Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-
- 485 Risk Women with a History of Gestational Diabetes Mellitus. *Clinical chemistry*.
- 486 2018;64(8):1203-1210.

487	29.	Bao W, Tobias DK, Bowers K, et al. Physical activity and sedentary behaviors associated
488		with risk of progression from gestational diabetes mellitus to type 2 diabetes mellitus: a
489		prospective cohort study. JAMA internal medicine. 2014;174(7):1047-1055.
490	30.	Bao W, Li S, Chavarro JE, et al. Low Carbohydrate-Diet Scores and Long-term Risk of
491		Type 2 Diabetes Among Women With a History of Gestational Diabetes Mellitus: A
492		Prospective Cohort Study. Diabetes care. 2016;39(1):43-49.
493	31.	Huvinen E, Eriksson JG, Koivusalo SB, et al. Heterogeneity of gestational diabetes
494		(GDM) and long-term risk of diabetes and metabolic syndrome: findings from the
495		RADIEL study follow-up. Acta diabetologica. 2018;55(5):493-501.
496	32.	Lauenborg J, Hansen T, Jensen DM, et al. Increasing incidence of diabetes after
497		gestational diabetes: a long-term follow-up in a Danish population. Diabetes care.
498		2004;27(5):1194-1199.
499	33.	Schaefer-Graf UM, Klavehn S, Hartmann R, et al. How do we reduce the number of
500		cases of missed postpartum diabetes in women with recent gestational diabetes mellitus?
501		Diabetes care. 2009;32(11):1960-1964.
502	34.	Linné Y, Barkeling B, Rössner S. Natural course of gestational diabetes mellitus: long
503		term follow up of women in the SPAWN study. BJOG : an international journal of
504		obstetrics and gynaecology. 2002;109(11):1227-1231.
505	35.	Gunderson EP, Hurston SR, Ning X, et al. Lactation and Progression to Type 2 Diabetes
506		Mellitus After Gestational Diabetes Mellitus: A Prospective Cohort Study. Annals of

507 *internal medicine*. 2015;163(12):889-898.

Lai M, Liu Y, Ronnett GV, et al. Amino acid and lipid metabolism in post-gestational

508

36.

509		diabetes and progression to type 2 diabetes: A metabolic profiling study. PLoS medicine.
510		2020;17(5):e1003112.
511	37.	Wahlberg J, Ekman B, Nyström L, Hanson U, Persson B, Arnqvist HJ. Gestational
512		diabetes: Glycaemic predictors for fetal macrosomia and maternal risk of future diabetes.
513		Diabetes research and clinical practice. 2016;114:99-105.
514	38.	Löbner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women
515		with gestational diabetes mellitus. Diabetes. 2006;55(3):792-797.
516	39.	Daly B, Toulis KA, Thomas N, et al. Increased risk of ischemic heart disease,
517		hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a
518		target group in general practice for preventive interventions: A population-based cohort
519		study. PLoS medicine. 2018;15(1):e1002488.
520	40.	Tam WH, Ma RC, Yang X, et al. Cardiometabolic risk in Chinese women with prior
521		gestational diabetes: a 15-year follow-up study. Gynecologic and obstetric investigation.
522		2012;73(2):168-176.
523	41.	Fan Y, Li W, Liu H, et al. Effects of obesity and a history of gestational diabetes on the
524		risk of postpartum diabetes and hyperglycemia in Chinese women: Obesity, GDM and
525		diabetes risk. Diabetes research and clinical practice. 2019;156:107828.
526	42.	Shen Y, Leng J, Li W, et al. Lactation intensity and duration to postpartum diabetes and
527		prediabetes risk in women with gestational diabetes. Diabetes/metabolism research and
528		reviews. 2019;35(3):e3115.

- 529 43. Wang L, Liu H, Zhang S, et al. Obesity index and the risk of diabetes among Chinese
- 530 women with prior gestational diabetes. *Diabetic medicine : a journal of the British*
- 531 *Diabetic Association*. 2014;31(11):1368-1377.
- 532 44. Yin P, Shao P, Liu H, et al. C-peptide levels and the risk of diabetes and pre-diabetes
- 533 among Chinese women with gestational diabetes. *Journal of diabetes and its*
- *complications*. 2017;31(12):1658-1662.
- 535 45. Yuan X, Liu H, Wang L, et al. Gestational hypertension and chronic hypertension on the
- risk of diabetes among gestational diabetes women. Journal of diabetes and its
- *complications.* 2016;30(7):1269-1274.
- 538 46. Göbl CS, Bozkurt L, Yarragudi R, et al. Biomarkers of endothelial dysfunction in relation
- to impaired carbohydrate metabolism following pregnancy with gestational diabetes
  mellitus. *Cardiovascular diabetology*. 2014;13:138.
- 541 47. Yefet E, Schwartz N, Sliman B, Ishay A, Nachum Z. Good glycemic control of
- 542 gestational diabetes mellitus is associated with the attenuation of future maternal
- 543 cardiovascular risk: a retrospective cohort study. *Cardiovascular diabetology*.
- 544 2019;18(1):75.
- 545 48. Weerasiri T, Riley SF, Sheedy MT, Walstab JE, Wein P. Amniotic fluid insulin values in
- 546 women with gestational diabetes as a predictor of emerging diabetes mellitus. *The*
- 547 Australian & New Zealand journal of obstetrics & gynaecology. 1993;33(4):358-361.
- 548 49. Hanson U, Persson B, Hartling SG, Binder C. Increased molar proinsulin-to-insulin ratio
- 549 in women with previous gestational diabetes does not predict later impairment of glucose
- 550 tolerance. *Diabetes care*. 1996;19(1):17-20.

551	50.	Pallardo F, Herranz L, Garcia-Ingelmo T, et al. Early postpartum metabolic assessment ir
552		women with prior gestational diabetes. <i>Diabetes care</i> . 1999;22(7):1053-1058.

- 553 51. Dehmer EW, Phadnis MA, Gunderson EP, et al. Association Between Gestational
- 554 Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young
- 555 Adults (CARDIA) Study. American journal of kidney diseases : the official journal of the
- *National Kidney Foundation.* 2018;71(1):112-122.
- 557 52. Tobias DK, Stuart JJ, Li S, et al. Association of History of Gestational Diabetes With
- 558 Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women.
- *JAMA internal medicine*. 2017;177(12):1735-1742.
- 560 53. Fadl H, Magnuson A, Östlund I, Montgomery S, Hanson U, Schwarcz E. Gestational
- 561 diabetes mellitus and later cardiovascular disease: a Swedish population based case-
- 562 control study. *BJOG* : an international journal of obstetrics and gynaecology.
- 563 2014;121(12):1530-1536.
- 564 54. Kaul P, Savu A, Nerenberg KA, et al. Impact of gestational diabetes mellitus and high
- 565 maternal weight on the development of diabetes, hypertension and cardiovascular
- 566 disease: a population-level analysis. *Diabetic medicine : a journal of the British Diabetic*
- 567 *Association*. 2015;32(2):164-173.
- 568 55. Pace R, Brazeau AS, Meltzer S, Rahme E, Dasgupta K. Conjoint Associations of
- 569 Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular
- 570 Disease in Parents: A Retrospective Cohort Study. *American journal of epidemiology*.
- 571 2017;186(10):1115-1124.

572	56.	Aris IM, Soh SE, Tint MT, et al. Associations of infant milk feed type on early postnatal

573 growth of offspring exposed and unexposed to gestational diabetes in utero. *European* 

*journal of nutrition*. 2017;56(1):55-64.

- 575 57. Boerschmann H, Pflüger M, Henneberger L, Ziegler AG, Hummel S. Prevalence and
- 576 predictors of overweight and insulin resistance in offspring of mothers with gestational
- 577 diabetes mellitus. *Diabetes care*. 2010;33(8):1845-1849.
- 578 58. Chen YL, Han LL, Shi XL, et al. Adverse pregnancy outcomes on the risk of overweight
  579 offspring: a population-based retrospective study in Xiamen, China. *Scientific reports*.
- 580 2020;10(1):1549.
- 58159.Crume TL, Ogden LG, Mayer-Davis EJ, et al. The impact of neonatal breast-feeding on582growth trajectories of youth exposed and unexposed to diabetes in utero: the EPOCH

583 Study. *International journal of obesity* (2005). 2012;36(4):529-534.

- 58460.Dugas C, Kearney M, Mercier R, et al. Early life nutrition, glycemic and anthropometric585profiles of children exposed to gestational diabetes mellitus in utero. *Early human*
- *development.* 2018;118:37-41.
- 587 61. Egeland GM, Meltzer SJ. Following in mother's footsteps? Mother-daughter risks for
- insulin resistance and cardiovascular disease 15 years after gestational diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2010;27(3):257-265.
- 590 62. Faith MS, Hittner JB, Hurston SR, et al. Association of Infant Temperament With
- 591 Subsequent Obesity in Young Children of Mothers With Gestational Diabetes Mellitus.
- *JAMA pediatrics*. 2019;173(5):424-433.
- 593 63. Gillman MW, Rifas-Shiman S, Berkey CS, Field AE, Colditz GA. Maternal gestational
- 594 diabetes, birth weight, and adolescent obesity. *Pediatrics*. 2003;111(3):e221-226.

- 595 64. Gunderson EP, Greenspan LC, Faith MS, Hurston SR, Quesenberry CP, Jr. Breastfeeding
- and growth during infancy among offspring of mothers with gestational diabetes mellitus:
- 597 a prospective cohort study. *Pediatric obesity*. 2018;13(8):492-504.
- 598 65. Hammoud NM, de Valk HW, Biesma DH, Visser GH. Intrauterine Adiposity and BMI in
- 599 4- to 5-Year-Old Offspring from Diabetic Pregnancies. *Neonatology*. 2017;111(2):177-
- 600 181.
- 601 66. Hammoud NM, Visser GHA, van Rossem L, Biesma DH, Wit JM, de Valk HW. Long-
- 602 term BMI and growth profiles in offspring of women with gestational diabetes.
- 603 *Diabetologia*. 2018;61(5):1037-1045.
- 604 67. Huang Y, Zhang W, Go K, et al. Altered growth trajectory in children born to mothers
- with gestational diabetes mellitus and preeclampsia. *Archives of gynecology and obstetrics*. 2020;301(1):151-159.
- 607 68. Hui LL, Li AM, Nelson EAS, Leung GM, Lee SL, Schooling CM. In utero exposure to
- 608 gestational diabetes and adiposity: does breastfeeding make a difference? *International*
- 609 *journal of obesity* (2005). 2018;42(7):1317-1325.
- 610 69. Ijäs H, Vääräsmäki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a
- 611 randomised study of metformin and insulin in gestational diabetes mellitus: growth and
- 612 development of the children at the age of 18 months. *BJOG : an international journal of*
- 613 *obstetrics and gynaecology.* 2015;122(7):994-1000.
- 614 70. Kaul P, Bowker SL, Savu A, Yeung RO, Donovan LE, Ryan EA. Association between
- 615 maternal diabetes, being large for gestational age and breast-feeding on being overweight
- 616 or obese in childhood. *Diabetologia*. 2019;62(2):249-258.

617	71.	Kelstrup	L. H	iort L.	Houshmand-	Deregaard A	. et al.	Gene Ex	pression	and DNA
0 <b>1</b> /	· · ·	1101001000	_,	1010	110000000000000000000000000000000000000		,	<b>C</b> • · · · · · · · · · · · · · · · · · ·	P1001011	

- 618 Methylation of PPARGC1A in Muscle and Adipose Tissue From Adult Offspring of
- 619 Women With Diabetes in Pregnancy. *Diabetes*. 2016;65(10):2900-2910.
- 620 72. Kubo A, Ferrara A, Windham GC, et al. Maternal hyperglycemia during pregnancy
- 621 predicts adiposity of the offspring. *Diabetes care*. 2014;37(11):2996-3002.
- 622 73. Landi SN, Radke S, Engel SM, et al. Association of Long-term Child Growth and
- 623 Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
- 624 JAMA pediatrics. 2019;173(2):160-168.
- 625 74. Leng J, Li W, Zhang S, et al. GDM Women's Pre-Pregnancy Overweight/Obesity and
- 626 Gestational Weight Gain on Offspring Overweight Status. *PloS one*.
- 627 2015;10(6):e0129536.
- 628 75. Liang Z, Liu H, Wang L, et al. Maternal Gestational Diabetes Mellitus Modifies the
- 629 Relationship Between Genetically Determined Body Mass Index During Pregnancy and
- 630 Childhood Obesity. *Mayo Clinic proceedings*. 2020;95(9):1877-1887.
- 631 76. Maslova E, Hansen S, Grunnet LG, et al. Maternal protein intake in pregnancy and
- offspring metabolic health at age 9-16 y: results from a Danish cohort of gestational
- 633 diabetes mellitus pregnancies and controls. *The American journal of clinical nutrition*.
- 634 2017;106(2):623-636.
- 635 77. Maslova E, Hansen S, Strøm M, et al. Fish Intake in Pregnancy and Offspring Metabolic
  636 Parameters at Age 9 16-Does Gestational Diabetes Modify the Risk? *Nutrients*.
- 637 2018;10(10).
- 638 78. Maslova E, Hansen S, Grunnet LG, et al. Maternal glycemic index and glycemic load in
- 639 pregnancy and offspring metabolic health in childhood and adolescence-a cohort study of

- 640 68,471 mother-offspring dyads from the Danish National Birth Cohort. *European journal*641 *of clinical nutrition*. 2019;73(7):1049-1062.
- 642 79. Nouhjah S, Shahbazian H, Latifi SM, Malamiri RA, Ghodrati N. Body mass index
- 643 growth trajectories from birth through 24 months in Iranian infants of mothers with
- 644 gestational diabetes mellitus. *Diabetes & metabolic syndrome*. 2019;13(1):408-412.
- 645 80. Pirkola J, Pouta A, Bloigu A, et al. Risks of overweight and abdominal obesity at age 16
- 646 years associated with prenatal exposures to maternal prepregnancy overweight and
- 647 gestational diabetes mellitus. *Diabetes care*. 2010;33(5):1115-1121.
- 648 81. Schaefer-Graf UM, Pawliczak J, Passow D, et al. Birth weight and parental BMI predict
- overweight in children from mothers with gestational diabetes. *Diabetes care*.
- 650 2005;28(7):1745-1750.
- 651 82. Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and

652 early childhood overweight in children from mothers with gestational diabetes mellitus.

- 653 *Diabetes care*. 2006;29(5):1105-1107.
- 654 83. Shi X, Wang D, Lin M, et al. MATERNAL GESTATIONAL DIABETES MELLITUS
- 655 AND OFFSPRING BODY MASS INDEX FROM 1 TO 4 YEARS. Endocrine practice :
- 656 official journal of the American College of Endocrinology and the American Association
- 657 *of Clinical Endocrinologists*. 2020;26(6):619-626.
- 658 84. Shearrer GE, Whaley SE, Miller SJ, House BT, Held T, Davis JN. Association of
- 659 gestational diabetes and breastfeeding on obesity prevalence in predominately Hispanic
- low-income youth. *Pediatric obesity*. 2015;10(3):165-171.

$001$ $00.$ Dioni $1$ $D_1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$	661	85.	Shokry E, Marchioro I	L. Uhl O.	et al. Transgo	enerational cycle	e of obesity	and diabete
---	-----	-----	-----------------------	-----------	----------------	-------------------	--------------	-------------

- 662 investigating possible metabolic precursors in cord blood from the PREOBE study. *Acta*
- 663 *diabetologica*. 2019;56(9):1073-1082.
- 664 86. Shub A, Churilov L, Miranda M, Georgiou HM, Lappas M. Postpartum maternal
- adipokines and infant weight for length at 1 year in women with gestational diabetes. *The*
- 666 journal of maternal-fetal & neonatal medicine : the official journal of the European
- 667 Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal
- 668 Societies, the International Society of Perinatal Obstet. 2019;32(9):1571-1574.
- 669 87. Song Q, Wang L, Liu H, et al. Maternal GDM Status, Genetically Determined Blood
- 670 Glucose, and Offspring Obesity Risk: An Observational Study. *Obesity (Silver Spring,*671 *Md*). 2021;29(1):204-212.
- 672 88. Vandyousefi S, Whaley SE, Widen EM, et al. Association of breastfeeding and early
- 673 exposure to sugar-sweetened beverages with obesity prevalence in offspring born to
- 674 mothers with and without gestational diabetes mellitus. *Pediatric obesity*.
- 675 2019;14(12):e12569.
- 676 89. Vohr BR, McGarvey ST. Growth patterns of large-for-gestational-age and appropriate-
- 677 for-gestational-age infants of gestational diabetic mothers and control mothers at age 1
  678 year. *Diabetes care*. 1997;20(7):1066-1072.
- 679 90. Vohr BR, McGarvey ST, Tucker R. Effects of maternal gestational diabetes on offspring
  680 adiposity at 4-7 years of age. *Diabetes care*. 1999;22(8):1284-1291.
- Wroblewska-Seniuk K, Wender-Ozegowska E, Szczapa J. Long-term effects of diabetes
  during pregnancy on the offspring. *Pediatric diabetes*. 2009;10(7):432-440.

683	92.	Zhang S, Liu H, Zhang C, et al. Maternal glucose during pregnancy and after delivery in

- 684 women with gestational diabetes mellitus on overweight status of their children. *BioMed*
- 685 *research international.* 2015;2015:543038.
- 686 93. Zhang S, Wang L, Leng J, et al. Hypertensive disorders of pregnancy in women with
- 687 gestational diabetes mellitus on overweight status of their children. *Journal of human*
- 688 *hypertension*. 2017;31(11):731-736.
- 689 94. Zhang T, Wang P, Liu H, et al. Physical Activity, TV Watching Time, Sleeping, and Risk
- 690 of Obesity and Hyperglycemia in the Offspring of Mothers with Gestational Diabetes
- 691 Mellitus. *Scientific reports*. 2017;7:41115.
- 692 95. Zhao YL, Ma RM, Lao TT, et al. Maternal gestational diabetes mellitus and overweight
- and obesity in offspring: a study in Chinese children. *Journal of developmental origins of health and disease*. 2015;6(6):479-484.
- 695 96. Zhu Y, Olsen SF, Mendola P, et al. Growth and obesity through the first 7 y of life in
- association with levels of maternal glycemia during pregnancy: a prospective cohort
- 697 study. *The American journal of clinical nutrition*. 2016;103(3):794-800.
- 698 97. Zhu Y, Olsen SF, Mendola P, et al. Maternal consumption of artificially sweetened
- beverages during pregnancy, and offspring growth through 7 years of age: a prospective
- cohort study. *International journal of epidemiology*. 2017;46(5):1499-1508.
- 701 98. Zhu Y, Olsen SF, Mendola P, et al. Maternal dietary intakes of refined grains during
- pregnancy and growth through the first 7 y of life among children born to women with
- gestational diabetes. *The American journal of clinical nutrition*. 2017;106(1):96-104.

704	99.	Kampmann FB, Thuesen ACB, Hjort L, et al. Exposure to Gestational Diabetes Is a
705		Stronger Predictor of Dysmetabolic Traits in Children Than Size at Birth. The Journal of
706		clinical endocrinology and metabolism. 2019;104(5):1766-1776.
707	100.	Kampmann FB, Thuesen ACB, Hjort L, et al. Increased leptin, decreased adiponectin and
708		FGF21 concentrations in adolescent offspring of women with gestational diabetes.
709		European journal of endocrinology. 2019;181(6):691-700.
710	101.	Vandyousefi S, Goran MI, Gunderson EP, et al. Association of breastfeeding and
711		gestational diabetes mellitus with the prevalence of prediabetes and the metabolic
712		syndrome in offspring of Hispanic mothers. Pediatric obesity. 2019;14(7):e12515.
713	102.	Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association
714		with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics.
715		2005;115(3):e290-296.
716	103.	Borgoño CA, Hamilton JK, Ye C, et al. Determinants of insulin resistance in infants at
717		age 1 year: impact of gestational diabetes mellitus. <i>Diabetes care</i> . 2012;35(8):1795-1797.
718	104.	Del Gobbo LC, Song Y, Elin RJ, Meltzer SJ, Egeland GM. Gestational glucose
719		intolerance modifies the association between magnesium and glycemic variables in
720		mothers and daughters 15 years post-partum. Magnesium research. 2012;25(2):54-63.
721	105.	Wilk M, Horodnicka-Józwa A, Moleda P, et al. Assessment of selected carbohydrate
722		parameters in children exposed to gestational diabetes in utero. Neuro endocrinology
723		letters. 2015;36(5):504-510.
724	106.	Dugas C, Bélanger M, Perron J, et al. Is A Healthy Diet Associated with Lower
725		Anthropometric and Glycemic Alterations in Predisposed Children Born from Mothers
726		with Gestational Diabetes Mellitus? Nutrients. 2019;11(3).

727	107.	Casey BM, Rice MM, Landon MB, et al. Effect of Treatment of Mild Gestational
728		Diabetes on Long-Term Maternal Outcomes. American journal of perinatology.
729		2020;37(5):475-482.
730	108.	Huang F, Zhang S, Tian Y, et al. Effect of mobile health based peripartum management of
731		gestational diabetes mellitus on postpartum diabetes: A randomized controlled trial.
732		Diabetes research and clinical practice. 2021;175:108775.
733	109.	Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a
734		history of gestational diabetes: effects of metformin and lifestyle interventions. The
735		Journal of clinical endocrinology and metabolism. 2008;93(12):4774-4779.
736	110.	Landon MB, Rice MM, Varner MW, et al. Mild gestational diabetes mellitus and long-
737		term child health. Diabetes care. 2015;38(3):445-452.
738	111.	Grotenfelt NE, Wasenius N, Eriksson JG, et al. Effect of maternal lifestyle intervention
739		on metabolic health and adiposity of offspring: Findings from the Finnish Gestational
740		Diabetes Prevention Study (RADIEL). Diabetes & metabolism. 2020;46(1):46-53.
741	112.	Keely EJ, Malcolm JC, Hadjiyannakis S, Gaboury I, Lough G, Lawson ML. Prevalence
742		of metabolic markers of insulin resistance in offspring of gestational diabetes
743		pregnancies. Pediatric diabetes. 2008;9(1):53-59.
744	113.	Malcolm JC, Lawson ML, Gaboury I, Lough G, Keely E. Glucose tolerance of offspring
745		of mother with gestational diabetes mellitus in a low-risk population. Diabetic medicine :
746		a journal of the British Diabetic Association. 2006;23(5):565-570.
747	114.	Battin MR, Obolonkin V, Rush E, Hague W, Coat S, Rowan J. Blood pressure
748		measurement at two years in offspring of women randomized to a trial of metformin for
749		GDM: follow up data from the MiG trial. BMC pediatrics. 2015;15:54.

750	115.	Rowan JA	. Rush EC.	Obolonkin V	. Battin M.	Wouldes T	. Hague	WM.	Metformin i	in
			,	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	,		,			

751 gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years

752 of age. *Diabetes care*. 2011;34(10):2279-2284.

- 753 116. Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS, Crowther CA. Effect of
- treatment of gestational diabetes mellitus on obesity in the next generation. *Diabetes*
- 755 *care*. 2010;33(5):964-968.
- 756 117. Francis EC, Kechris K, Cohen CC, Michelotti G, Dabelea D, Perng W. Metabolomic
- 757 Profiles in Childhood and Adolescence Are Associated with Fetal Overnutrition.
- 758 *Metabolites.* 2022;12(3).
- Perng W, Oken E, Dabelea D. Developmental overnutrition and obesity and type 2
  diabetes in offspring. *Diabetologia*. 2019;62(10):1779-1788.
- 119. Liu H, Zhang S, Wang L, et al. Fasting and 2-hour plasma glucose, and HbA1c in
- pregnancy and the postpartum risk of diabetes among Chinese women with gestational
  diabetes. *Diabetes research and clinical practice*. 2016;112:30-36.
- 120. Dornhorst A, Bailey PC, Anyaoku V, Elkeles RS, Johnston DG, Beard RW. Abnormalities
- 765 of glucose tolerance following gestational diabetes. *The Quarterly journal of medicine*.
- 766 1990;77(284):1219-1228.
- 767 121. Zhang C, Olsen SF, Hinkle SN, et al. Diabetes & Women's Health (DWH) Study: an
- 768 observational study of long-term health consequences of gestational diabetes, their
- 769 determinants and underlying mechanisms in the USA and Denmark. *BMJ open*.
- 770 2019;9(4):e025517.

- 771 122. Vääräsmäki M, Pouta A, Elliot P, et al. Adolescent manifestations of metabolic syndrome
- among children born to women with gestational diabetes in a general-population birth
- cohort. American journal of epidemiology. 2009;169(10):1209-1215.

774

Author Year	Country	Study name or site (Year of birth)	Exposure	Maternal outcome(s) or offspring outcome(s)	Method of GDM ascertainment	Sample Size
			MATERNAL OUTCOMES			
Ratner 2008 <sup>109</sup>	USA	RCT, Diabetes Prevention Program (DPP)	Maternal life-course	T2D	Self-report	350
Gillman 2010 <sup>116</sup>	Australia	Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS)	Perinatal/postpartum	Anthropometrics	Not specified	199
Ijäs 2015 <sup>69</sup>	Finland	RCT (NCT01087866), Oulu University Hospital (2005-2007)	Perinatal/postpartum	Anthropometrics	Not specified	93
Huvinen 2018 <sup>31</sup>	Finland	Finnish Gestational Diabetes Prevention Study (RADIEL)	Perinatal/postpartum	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Biochemical test	Maternal: 179 Offspring: 127
Landon 2015 <sup>110</sup> , Varner 2017 <sup>4</sup>	USA	RCT, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network	Perinatal/postpartum	Maternal: T2D; Offspring: T2D; CVD composite; Other: Metabolic syndrome; Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Biochemical test	Maternal: 457 Offspring: 500
Battin 2015 <sup>114</sup> , Rowan 2011 <sup>115</sup>	New Zealand	Metformin in Gestational diabetes (MiG): the offspring follow-up (TOFU) ACTRN12605000311651)	Perinatal/postpartum	Anthropometrics; Cardiometabolic biomarkers		
Hanson 1996 <sup>49</sup>	Sweden	RCT, Karolinska Hospital and St. Goran's Hospital (1981-1984)	Maternal life-course	T2D	Not specified	97
Keely 2008 <sup>112</sup> , Malcolm 2006 <sup>113</sup>	Canada	RCT, Ottawa Hospital Ontario (1991-1995)	Perinatal/postpartum; Offspring life-course	Glycemic traits; Cardiometabolic biomarkers; Metabolomic syndrome; T2D		
Liu 2014 <sup>6</sup> , Fan 2019 <sup>41</sup> , Li 2014 <sup>7</sup> , Li 2019 <sup>5</sup> , Liu 2016 <sup>119</sup> , Wang 2014 <sup>43</sup>	China	Tianjin Gestational Diabetes Mellitus Prevention Program	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D		
Pallardo 1999 <sup>50</sup>	Spain	University Hospital La Paz, Madrid (1987-1997)	Social/environmental/genetic; Perinatal/postpartum	T2D	Biochemical test	788
Myers 2014 <sup>19</sup>	UK	St. Mary's Hospital, Manchester	Social/environmental/genetic	T2D	Biochemical test	629

TABLE 1. Summary of studies included in this systematic review, stratified by maternal, offspring, and maternal and offspring outcomes.

		(2003-2013)				
Dornhorst 1990 <sup>120</sup>	UK	St. Mary's Hospital, London (1976-1982)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	56
Linne 2002 <sup>34</sup>	Sweden	Stockholm Pregnancy and Women's Nutrition (SPAWN) study	Perinatal/postpartum; Maternal life-course	T2D	Medical records	28
Vince 2018 <sup>3</sup>	Croatia	CroDiab National Registry	Perinatal/postpartum	T2D	Medical records	853
Zhang 2019 <sup>121</sup> , Ley 2020 <sup>26</sup>	Denmark and USA	Diabetes & Women's Health (DWH) Study	Perinatal/postpartum	T2D	Self-report	7759
Akinci 2011 <sup>18</sup>	Turkey	Dokuz Eylul University Hospital, Izmir (2002-2008)	Perinatal/postpartum	T2D	Biochemical test	195
Yefet 2019 <sup>47</sup>	Israel	Emek Medical Center (1991-2011)	Perinatal/postpartum	T2D	Biochemical test	446
Lobner 2006 <sup>38</sup>	Germany	German GDM Prospective Study, Births 1989-1999	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	302
Retnakaran 2015 <sup>14</sup>	Canada	Ontario births 200-2010	Perinatal/postpartum; Offspring life-course	T2D	Medical records	23302
Steinhart 1997 <sup>8</sup>	USA	Indian Health Service	Perinatal/postpartum	T2D	Medical records	111
Lin 2016 <sup>16</sup>	Taiwan	Kaohsiung Medical University (2011)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	130
Hakkarainen 2018 <sup>9</sup>	Finland	Kuopio University Hospital, Births 1989-2009	Perinatal/postpartum	T2D	Medical records	444
Wang 2012 <sup>10</sup>	USA	Louisiana State University Hospital	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	1142
Chodick 2010 <sup>11</sup>	Israel	Maccabi Healthcare Services (1995-2009)	Perinatal/postpartum	T2D	Medical records; Biochemical test	11270
Lappas 2015 <sup>12</sup>	Australia	Mercy Hospital for Women, Melbourne (2003-2005)	Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	104
Lee 2007 <sup>13</sup>	Australia	Mercy Hospital for Women, Melbourne (1971-2003)	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course	T2D	Medical records	5,470
Weerasiri 1993 <sup>48</sup>	Australia	Mercy Hospital for Women, Melbourne (1985-1992)	Perinatal/postpartum	T2D	Biochemical test	216
Schaefer-Graf 2009 <sup>33</sup>	Germany	Multi-Center (2000-2005)	Perinatal/postpartum	T2D	Medical records	605
Kugishima 2018 <sup>22</sup>	Japan	Nagasaki Medical Center (2003- 2014)	Social/environmental/genetic; Perinatal/postpartum	T2D	Biochemical test	306
Kawasaki 2020 <sup>15</sup>	Japan	National Center for Child Health and Development Tokyo, Osaka Women's and Children's Hospital, Nagasaki Medical	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	399

		Center (1995-2011)				
Tseng 2008 <sup>23</sup>	Taiwan	National Health Insurance Database (NR)	Social/environmental/genetic	T2D	Self-report	510
Eades 2015 <sup>21</sup>	Scotland	Ninewells Hospital, Dundee (1994-2004)	Social/environmental/genetic; Perinatal/postpartum	T2D	Medical records	164
<b>Rivero 2008</b> <sup>17</sup>	Brazil	Pe. Jeremias' Hospital	Perinatal/postpartum; Maternal life-course	T2D	Biochemical test	109
Fadl 2014 <sup>53</sup>	Sweden	Swedish Medical Birth Register (SMBR)	Perinatal/postpartum Maternal life-course	T2D; CVD	Biochemical test	15949
Kaul 2015 <sup>54</sup>	Canada	Alberta Perinatal Health Program	Perinatal/postpartum	T2D; CVD	Medical records	8731
Gunderson 2018 <sup>2</sup>	USA	Coronary Artery Risk Development in Young Adults (CARDIA)	Social/environmental/genetic; Maternal life-course Perinatal/Postpartum	T2D, CKD	Self-report	155
Pintaudi 2015 <sup>20</sup>	Italy	National Health System Registry, Puglia (2002-2010)	Perinatal/postpartum	T2D; CVD	Medical records	3851
Bao 2014 <sup>29</sup> , Bao 2015 <sup>24</sup> , Bao 2016 <sup>30</sup> , Tobias 2017 <sup>52</sup>	USA	Nurses' Health Study II	Perinatal/postpartum; Maternal life-course; Social/environmental/genetic;	T2D; CVD	Self-report	5292
			OFFSPRING OUTCOMES			
Huang 2020 <sup>67</sup>	USA	Stress in Pregnancy Study (SIPS)	Perinatal/postpartum	Anthropometrics	Medical records	26
Hammoud 2017 <sup>65</sup>	Netherlands	University Medical Center Utrecht	Perinatal/postpartum	Anthropometrics	Medical records	104
Shearrer 2015 <sup>84</sup>	USA	Women, Infants and Children Program, Los Angeles County	Perinatal/postpartum; Offspring life-course	Anthropometrics	Self-report	470

			Perinatal/postpartum; Offspring life-course Perinatal/postpartum			
Shub 2019 <sup>86</sup>	Australia	Mercy Hospital for Women, Melbourne (NR)	Perinatal/postpartum	Anthropometrics	Biochemical test	160
Nouhjah 2019 <sup>79</sup>	Iran	Ahvazin (2014-2016)	Perinatal/postpartum	Anthropometrics	Biochemical test	438
Kaul 2019 <sup>70</sup>	Canada	Calgary Region, Births 2005- 2013	Perinatal/postpartum	Anthropometrics	Medical records	5136
Hui 2018 <sup>68</sup>	China	Children of 1997 Birth Cohort	Perinatal/postpartum	Anthropometrics	Self-report	539
Kubo 2014 <sup>72</sup>	USA	Cohort Study of Young Girls' Nutrition, Environment, and Transitions (CYGNET)	Perinatal/postpartum	Anthropometrics	Medical records	27
Schaefer-Graf 2005 <sup>81</sup> , Schaefer- Graf 2006 <sup>82</sup>	Germany	Diabetes Prenatal Care Clinic of the Department of Obstetrics at the Vivantes Medical Center Berlin	Social/environmental/genetic; Perinatal/postpartum; Offspring life-course	Anthropometrics	Medical records; Biochemical test	324
Zhao 2015 <sup>95</sup>	China	First Affiliated Hospital of Kunming Medical University, Births 2003-2011	Perinatal/postpartum; Offspring life-course	Anthropometrics	Biochemical test	1068
Aris 2017 <sup>56</sup>	Singapore	Growing Up in Singapore Towards Healthy Outcomes (GUSTO) Study	Perinatal/postpartum; Offspring life-course	Anthropometrics	Biochemical test	181
Gillman 2003 <sup>63</sup>	USA	Growing Up Today Study (GUTS) and Nurses' Health Study II	Perinatal/postpartum	Anthropometrics	Self-report	14,881
Landi 2019 <sup>73</sup>	New Zealand	National Maternity Collection (MAT)	Perinatal/postpartum; Offspring life-course	Anthropometrics	Medical records	3,928

Social/environmental/genetic; Anthropometrics

Chen 2020<sup>58</sup>

China

Xiamen Medical Birth Registry

6778

Medical records

Crume 2012 <sup>59</sup>	USA	Exploring Perinatal Outcomes among CHildren (EPOCH)	Social/environmental/genetic Perinatal/postpartum; Offspring life-course	Anthropometrics; Cardiometabolic biomarkers	Medical records	94
Wroblewska- Seniuk 2009 <sup>91</sup>	Poland	Clinical Hospital of Obstetrics and Gynecology, Poznan	Perinatal/postpartum	Anthropometrics; Glycemic traits	Not specified	34
Boerschmann 2010 <sup>57</sup>	Germany	German GDM Offspring Study, Births 1989-2000	Perinatal/postpartum	Anthropometrics; Glycemic traits	Medical records	232
Shokry 2019 <sup>85</sup>	Spain	PREOBE Study (NCT01634464; 2008-2012)	Perinatal/postpartum	Anthropometrics; Novel 'omics; Other: The novel 'omics is cord blood metabolomics	Not specified	27
Zhu 2016 <sup>96</sup> , Zhu 2017 <sup>97</sup> , Zhu 2017 <sup>98</sup> , Maslova 2019 <sup>78</sup> , Maslova 2018 <sup>77</sup> , Maslova 2017 <sup>76</sup> , Kampmann 2019 <sup>99</sup> , Kampmann 2019 <sup>100</sup>	Denmark	Danish National Birth Cohort (DNBC)	Perinatal/Postpartum; Offspring Life-Course	Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Self-report; Medical records	918
Wilk 2015 <sup>105</sup>	Poland	Pomeranian Medical University, Szczecin (NR)	Offspring life-course	Glycemic traits	Not specified	50
		MATERN	AL AND OFFSPRING OUTC	OMES		
Lauenborg 2004 <sup>32</sup>	Denmark	Rigshospitalet, Denmark (1978- 1985, 1987-1996)	Social/environmental/genetic; Perinatal/postpartum; Maternal life-course; Offspring life-course	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Other: GLP-1, GIP, Glucagon; Glycemic traits; Novel 'omics; T2D; Metabolomic syndrome	Not specified	
DelGobbo 2012 <sup>104</sup>	Canada	Royal Victoria Hospital (1989- 1991)	Perinatal/postpartum; Maternal life-course	Maternal: T2D; Offspring: Anthropometrics; Glycemic traits; Cardiometabolic biomarkers	Not specified	

Vääräsmäki	Finland	Northern Finland Birth Cohort of	Perinatal/postpartum	Maternal: T2D	Biochemical test	Maternal: 139
2009 <sup>122</sup> , Pirkola		1986		Offspring:		Offspring: 95
2010 <sup>80</sup> , Pirkola				Anthropometrics;		
<b>2010</b> <sup>25</sup>				Glycemic traits;		
				Cardiometabolic		
				biomarkers; Metabolomic		
				syndrome		
Gunderson 2015 <sup>35</sup> ,	USA	Study of Women, Infant Feeding	Social/environmental/genetic;	Maternal: T2D	Medical records	Maternal: 959
Lai 2020 <sup>36</sup> , Faith		and Type 2 Diabetes after GDM	Perinatal/postpartum;	Offspring:		Offspring: 464
2019 <sup>62</sup> , Gunderson		Pregnancy (SWIFT) Study	Maternal life-course	Anthropometrics		
<b>2018</b> <sup>64</sup>						

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; GLP – glucagon-like peptide; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes.

Author Year	Trial/ Cohort/ Registry	Perinatal/ Postpartum	Maternal Lifecour	se Social/ En Genetic	vironment/
Kaul 2015 <sup>54</sup>	Alberta Perinatal Health Program & Alberta Ministry of Health	Pre-pregnancy BMI	1		
Gunderson 2018 <sup>2</sup>	Coronary Artery Risk Development in Young Adults (CARDIA)	Breastfeeding	Ļ		
Vince 2018 <sup>3</sup>	CroDiab registry	Pre-pregnancy BMI	1	Education	n.s.
				Marital Sta	tus n.s.
Varner 2017 <sup>4</sup>	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal- Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Parity	Î		
Li 2019 <sup>5</sup>	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	Pre-pregnancy BMI	1	Family hist	ory ofT2D ↑
		Pregnancy Complication	↑		
		GDM severity	$\uparrow$		
		Age at Pregnancy	n.s.		
Liu 2014 <sup>6</sup>	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	Pre-pregnancy BMI	↑ Weight Gain	Î	
Liu 2016 <sup>119</sup>	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	GDM severity	ſ		

# **TABLE 2**. Observational studies evaluating prognostic factors associated with incident T2D among women with a history of GDM (n=51). **Exposures and associations with incident T2D**

Li 2014 <sup>7</sup>	Follow up of Tianjin Gestational Diabetes Prevention Program			BMI	Î		
Steinhart 1997 <sup>8</sup>	Indian Health Service	Parity	1	BMI	1		
		GDM severity	1				
		Maternal age	1				
		Offspring birthweight	1				
Hakkarainen 2018 <sup>9</sup>	Kuopio University Hospital	Offspring birthweight	ſ				
Wang 2012 <sup>10</sup>	Louisiana State University Hospital- Based Longitudinal Study					Race (African American vs. White)	n.s.
Chodick 2010 <sup>11</sup>	Maccabi Healthcare Services (MHS)	Parity (≥4 vs. 1)	ſ	BMI	ſ	SES (lowest vs. highest)	1
		GDM severity	Ţ	Smoking (current/past vs. never)	n.s.		
Lappas 2015 <sup>12</sup>	Mercy Health	Novel biomarkers (cholesteryl ester species CE 20:4, the alkenylphosphatidylethanolamine species PE(P-36:2) and the phosphatidylserine species PS 38:4)	Ţ				
Lee 2007 <sup>13</sup>	Mercy Hospital for Women in Melbourne, Australia	GDM severity	1			Race (Asian vs. White)	↑
		Offspring birthweight	1				
Retnakaran 2015 <sup>14</sup>	Ministry of Health and Long-Term Care of Ontario	Offspring sex (Girl vs Boy)	ſ				
Kawasaki 2020 <sup>15</sup>	n/a	Pre-pregnancy BMI	1				
		GDM severity	1				
Lin 2016 <sup>16</sup>	n/a	Pre-pregnancy BMI	1				
		GDM severity	1				
		Offspring birthweight	n.s.				
		Pregnancy complication	n.s.				

Rivero 2008 <sup>17</sup>	N/A	Pre-pregnancy BMI	1	BMI	1		
				Blood Pressure	1		
				Lipids	1		
				Clinical Markers (CRP)	1		
Akinci 2011 <sup>18</sup>	N/A	GDM severity	1				
		Pre-pregnancy BMI	n.s.				
Myers 2014 <sup>19</sup>	N/A					Race (Asian vs. White)	1
Pintaudi 2015 <sup>20</sup>	N/A	Pregnancy complication	1				
Eades 2015 <sup>21</sup>	N/A	Pregnancy BMI	1				
		GDM severity	1				<u> </u>
Kugishima 2018 <sup>22</sup>	National Hospital OrganizationNagasaki Medical Center, Omura, Japan	GDM severity	Ţ				
Tseng 2008 <sup>23</sup>	National Taiwan University College of Medicine					Family history of T2D	n.s.
Bao 2015 <sup>24</sup>	NHS II, Diabetes & Women's Health Study	Weight gain	↑	BMI	1		
		Pregnancy BMI	1				
Pirkola 2010 <sup>25</sup>	Northern Finland Birth Cohort of 1986	Pre-pregnancy BMI	1				
Ley 2020 <sup>26</sup>	Nurses' Health Study (NHS) II and Diabetes in Women's Health (DWH) Study	Breastfeeding	Ļ				
Tobias 2012 <sup>27</sup>	Nurse's Health Study II			Diet	$\downarrow$		
Tobias 2018 <sup>28</sup>	Nurse's Health Study II			Novel biomarker (Branched chain amino acid)	1		
Bao 2014 <sup>29</sup>	Nurses' Health Study II who had a history of GDM, as part of the ongoing Diabetes & Women's Health Study			Physical activity	Ļ		

Bao 2016 <sup>30</sup>	Nurses' Health Study II who had a history of GDM, as part of the ongoing Diabetes & Women's Health Study			Diet (high protein/ fat from animal source)	↑		
				Diet (plant protein)	n.s.		
Huvinen 2018 <sup>31</sup>	RADIEL	Pre-pregnancy BMI	1				
Lauenborg 2004 <sup>32</sup>	Rigshospitalet Old Cohort, Rigshospitalet New Cohort	Pre-pregnancy BMI	1				
		GDM severity	1			Family history of T2D	1
		Pregnancy complication	n.s.			Race (Nordic vs. non- Nordic)	n.s.
Schaefer-Graf 2009 <sup>33</sup>	N/A	Novel niomarker (risk score: composite of pre-pregnancy BMI, gestational age at diagnosis, and GDM severity)	Ť				
Linné 2002 <sup>34</sup>	Stockholm Pregnancy and Women's Nutrition (SPAWN) study	Pre-pregnancy BMI	n.s.	BMI	Î		
		Parity	n.s.	Clinical Biomarkers	n.s.		
Gunderson 2015 <sup>35</sup>	SWIFT Cohort	Breastfeeding	$\downarrow$				
Lai 2020 <sup>36</sup>	SWIFT Cohort			Metabolomic profile	1		
Wahlberg 2016 <sup>37</sup>	Swedish Medical Birth Registry (SMBR) in 1902	GDM severity	Ť			Race (non-European vs. European)	1
		Pre-pregnancy BMI	1				
Lobner 2006 <sup>38</sup>	The German GDM Prospective Study	Pre-pregnancy BMI	Î				
		Parity	1				
		GDM severity	1				
		Novel biomarker (auto-antibodies to GAD and/or IA2)	Î				
Daly 2018 <sup>39</sup>	The Health Improvement Network (THIN) database					Race (Afro-Caribbean and South Asian vs. other)	↑

Tam 2012 <sup>40</sup>	N/A	Pregnancy BMI	1	Hypertension	<u> </u>
				Clinical markers (lipids and glycemic tests)	n.s.
Fan 2019 <sup>41</sup>	Tianjin GDM Screening Project	Pre-pregnancy BMI	1		
		Postpartum BMI	1		
Shen 2019 <sup>42</sup>	Tianjin GDM Screening Project	Breastfeeding	Ļ		
Wang 2014 <sup>43</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program			BMI	1
Yin 2017 <sup>44</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program			Clinical biomarkers	1
Yuan 2016 <sup>45</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program	Pregnancy complications	Î	Chronic hypertension	1
Gobl 2014 <sup>46</sup>	Vienna Post-Gestational Diabetes Project			Novel biomarker (sICAM and sE- selectin)	↑
Yefet 2019 <sup>47</sup>	N/A	GDM severity	1		
Weerasiri 1993 <sup>48</sup>	N/A	Novel biomarker (amniotic fluid insulin)	1		
Hanson 1996 <sup>49</sup>	N/A			Novel biomarker (Proinsulin:Insulin)	n.s.
Pallardo 1999 <sup>50</sup>	N/A	Pre-pregnancy BMI	1		
		GDM severity	1		
		Parity	n.s.		
		Previous pregnancy complications	n.s.		
		Offspring birthweight	n.s.		

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; n.s. - not significant; SES – socioeconomic status; T2D – type 2 diabetes.

**TABLE 3**. Randomized controlled trials (RCT) evaluating prognostic factors associated with incident type 2 diabetes (T2D) among women with a history of GDM (n=3).

		Intervention/exposure and association with	
Author Year	Trial/ Cohort/ Registry	T2D	
Casey 2020 <sup>107</sup>	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network's multicenter randomized controlled treatment trial		
	randomized controlled treatment that	Diet (formal nutritional counseling and diet therapy with insulin vs. usual prenatal care)	n.s.
Huang 2021 <sup>108</sup>	N/A	GDM severity	↑
		Mobile management	n.s.
Ratner 2008 <sup>109</sup>	Diabetes Prevention Program (DPP)	Intensive lifestyle + Metformin	<b>↑</b>

Abbreviations: GDM - gestational diabetes mellitus; n.s. - not significant

**TABLE 4**. Observational studies evaluating prognostic factors associated with cardiovascular disease (CVD) among women with a history of GDM (n=6).

		E	xpo	sures and associations with	n CV	D	
Author (year)	Trial/ Cohort/ Registry	Perinatal/ Postpartum		Maternal Lifecourse		Social/ Environn Genetic	nent/
	The Coronary Artery Risk Development in						
Dehmer 2018* <sup>51</sup>	Young Adults (CARDIA) Study					Race (Black vs. White)	↑
	Nurses' Health Study	Day and on on DMI	*	Haakhay Lifestala Saara	I	Family history of	
Tobias 2017 <sup>52</sup>	II (NHS II)	Pre-pregnancy BMI		Diagnosed with T2D	<u>↓</u> ↑		n.s.
	Swedish Medical	Pregnancy BMI	1	Smoking	$\uparrow$		
Fadl 2014 <sup>53</sup>	Birth Register (SMBR)			Chronic hypertension	n.s	8.	
Pintaudi 2015 <sup>20</sup>	N/A	Pregnancy complications	Î				
	Alberta Perinatal Health Program & Alberta Ministry of						
Kaul 2015 <sup>54</sup>	Health			BMI	Î		
Pace 2017 <sup>55</sup>	N/A	Pregnancy Complications (gestational hypertension)	1				

Abbreviations: BMI – body mass index; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; n.s. - not significant; T2D – type 2 diabetes.

\*Association with chronic kidney disease (CKD) outcome

<sup>‡</sup>Healthy lifestyle score included a combination of diet, BMI, physical activity, and smoking.

			E	xposure		
Author Year	Trial/Cohort/Registry Name	Age of outcome assessment	Maternal	Offspring	Offspring Outcome	Associatio n
Aris 2017 <sup>56</sup>	Growing up today in Singapore (GUSTO) study	24-36 months	Breastfeeding		Weight	n.s.
					BMI	n.s.
Boerschmann 2010 <sup>57</sup>		11 years	Pre-pregnancy BMI		Weight	Ţ
			Pregnancy Smoking		Weight	1
				Birthweight	Weight	n.s.
Chen 2020 58	Medical Birth Registry of Xiamen	1-5 years		Birthweight	BMI	1
					Weight	n.s.
Crume 2012 <sup>59</sup>	Exploring Perinatal outcomes Among CHildren (EPOCH) study	2-13 years	Breastfeeding		BMI	Ļ
Dugas 2018 <sup>60</sup>		2-14 years	Breastfeeding		Weight	n.s.

**TABLE 5.** Observational studies evaluating prognostic factors in relation to anthropometric outcomes among offspring exposed to GDM *in utero* (*n*=43).

					Waist Circumference	n.s.
					Fat Mass	n.s.
					Lean Fat Mass	n.s.
Egeland 2010 <sup>61</sup>	N/A	15 years	GDM Severity		BMI	n.s.
					Body fat	n.s.
Faith 2019 62	SWIFT Cohort	2-5 years	Breastfeeding		Obesity	$\downarrow$
Gillman 2003 <sup>63</sup>	Growing Up Today Study and Nurses' Health Study II	9-14 years		Birthweight	Overweight	n.s.
Gunderson 2018 <sup>64</sup>	SWIFT Offspring Study	12 months	Breastfeeding (vs. Formula)		Weight	Ţ
Hammoud 2017 <sup>65</sup>	University Medical Center Utrecht Women with a pregnancy complicated by type 1, type 2, or gestational diabetes who delivered in the University Medical Center Utrecht, the Netherlands, between 2000 and 2006	4-6 years		Birthweight	BMI	Ţ
Hammoud 2018 <sup>66</sup>		1-14 years		Birthweight	BMI	n.s.

Huang 2020 <sup>67</sup>	SIPS	5 years	Pregnancy Complications		BMI	1
Hui 2018 <sup>68</sup>	Children of 1997	16 years	Breastfeeding		Obesity	n.s.
Ijäs 2015 <sup>69</sup>	Follow-up of RCT of GDM requiring pharmacological treatment at Oulu University Hospital and secondary-level Kainuu Central Hospital	18 months	GDM Severity		Weight	1
Kaul 2019 <sup>70</sup>	Calgary Zone	4-6 years	Breastfeeding	LGA	Obesity	$\downarrow$
			Breastfeeding	Normal Weight	Obesity	n.s.
Kelstrup 2016 <sup>71</sup>	N/A	27-34 years	Gene Expression (Adipose Tissue: PPARGC1A)		Body fat	Ţ
					BMI	$\downarrow$
Kubo 2014 <sup>72</sup>	Cohort Study of Young Girls' Nutrition, Environment, and Transitions (CYGNET)	10-12 years	Pre-pregnancy BMI		BMI	Î
					Percent Body Fat	1
					Waist:Hip	$\uparrow$

Landi 2019 73	N/A	5 years	GDM Severity	Weight	n.s.
Leng 2015 <sup>74</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	Pre-pregnancy BMI & Gestational BMI	BMI	↑
				Weight	↑
Liang 2020 75	Follow up of Tianjin Gestational Diabetes Mellitus Prevention Program	6 years	BMI Genetic Risk Score	BMI	Î
	C			Waist Circumference	↑
				Fat Mass	Ŷ
Maslova 2017 <sup>76</sup>	Danish National Birth Cohort	9-12 years	Diet (Protein Intake)	Abdominal Fat	n.s.
				Total Fat	n.s.
Maslova 2018 77	Danish National Birth Cohort	9-16 years	Diet (fatty fish intake)	BMI	1
				Waist Circumference	↑
Maslova 2019 <sup>78</sup>	Danish National Birth Cohort (DNBC)	12 months - 7 years	Pregnancy Diet (Glycemic index and glycemic load)	Fat Mass	n.s.

					BMI	n.s.
Nouhjah 2019 79	Ahvazin children born between 2014 and 2016 were enrolled in this study	2 years		Sex (Boy vs Girl)	BMI	↑
	·				Weight	n.s.
Pirkola 2010 <sup>80</sup>	Northern Finland Birth Cohort of 1986	16 years	Pre-pregnancy BMI		Weight	1
					Abdominal Fat	↑
Schaefer-Graf 2005 <sup>81</sup>		2-8 years	Pre-pregnancy BMI and GDM severity		BMI	n.s.
			Lifecourse BMI		BMI	↑
				Neonatal BMI	BMI	↑
				Abdominal circumferen ce	BMI	n.s.
Schaefer-Graf 2006 <sup>82</sup>		2-8 years	Breastfeeding		Weight	$\downarrow$
			Breastfeeding + BMI		Weight	$\downarrow$
Shi 2020 <sup>83</sup>	Medical Birth Registry of Xiamen	1-4 years	GDM Severity		BMI	n.s.

				Weight	n.s.
Shearrer 2015 <sup>84</sup>	Women, Infants and Children Program in Los Angeles County	2-4 years	Breastfeeding	BMI	Ļ
Shokry 2019 <sup>85</sup>	PREOBE study	1 year	Cord blood biomarkers	BMI	Ť
Shub 2019 <sup>86</sup>		1 year	Leptin and Adiponectin	Weight	n.s.
Song 2021 <sup>87</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program	6 years	Genetic Risk Score	Weight	n.s.
Vandyousefi 2019 <sup>88</sup>	2014 Los Angeles County WIC Survey	1-5 years	Breastfeeding	BMI	$\downarrow$
Vohr 1997 <sup>89</sup>	N/A	1 year	Birthy	weight BMI	ſ
				Waist Circumference	ſ
				Skinfold	<b>↑</b>
Vohr 1999 <sup>90</sup>	N/A	4-7 years	Birthy	weight BMI	↑
				Waist Circumference	n.s.
				Skinfold	<b>↑</b>
Wroblewska-Seniuk 2009 91	N/A	4-9 years	GDM Severity	BMI	n.s.

					Waist Circumference	n.s.
Zhang 2015 92	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	GDM Severity		BMI	↑
Zhang 2017 93	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years	Pregnancy Complications		BMI	↑
Zhang 2017 94	Tianjin Gestational Diabetes Mellitus Prevention Program	1-5 years		Physical Activity (TV watching)		Ţ
Zhao 2015 95		5-10 years	Breastfeeding	Weight	BMI	$\downarrow$
				Sex (Female)	BMI	$\downarrow$
				Weight	BMI	n.s.
Zhu 2016 96	Danish National Birth Cohort (DNBC)	7 years	GDM Severity		BMI	1
Zhu 2017 97	Danish National Birth Cohort (DNBC)	7 years	Diet (Sugar- sweetened beverage)		BMI	↑
Zhu 2017 <sup>98</sup>	Danish National Birth Cohort (DNBC)	7 years	Diet (refined grain)		BMI	↑

Author Year	Trial Name	Intervention and/or Exposure	Offspring Outcome	Association
Rowan 2011	Metformin in Gestational diabetes (MiG): the offspring follow-up (TOFU)	Treatment (Metformin vs Insulin)	Skinfold	1
			Waist circumference	n.s.
			Total fat	n.s.
Gillman 2010	Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS)	Treatment (dietary advice, blood glucose monitoring, and insulin therapy) vs. Routine Care	BMI	n.s.
Landon 2015	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Treatment (dietary advice, blood glucose monitoring, and insulin therapy) vs. Routine Care	BMI	n.s.
			Waist circumference	n.s.
Malcolm 2006 <sup>113</sup>	N/A	Tight vs minimal intervention	Weight	n.s.

**TABLE 6.** Randomized control trials evaluating prognostic factors associated with anthropometric outcomes among offspring exposed to GDM *in utero* (n=4).

**TABLE 7**. Observational studies evaluating prognostic factors in relation to cardiometabolic outcomes among offspring exposed to GDM *in utero* (n=14).

		Exposi	ire		
Author Year	Trial/Cohort/Registry Name	Maternal	Offspring	Offspring Outcome	Association
Maslova 2019 <sup>78</sup>	Danish National Birth Cohort (DNBC)	Pregnancy Diet (Glycemic index and glycemic load)		HOMA-IR	n.s.
				MetS	n.s.
Maslova 2018 <sup>77</sup>	Danish National Birth Cohort (DNBC)	Diet (only fish intake)		MetS	n.s.
				Lipids	n.s.
				HOMA-IR	n.s.
Kampmann 2019 <sup>99</sup>	Danish National Birth Cohort (DNBC)		Birthweight	Fasting glucose	n.s.
				Insulin	n.s.
				C-peptide	n.s.
				HOMA-IR	n.s.

				Lipids	n.s.
Kampmann 2019 <sup>100</sup>	Danish National Birth Cohort	Pre-pregnancy BMI		Leptin	1
Vandyousefi 2019 <sup>101</sup>	SOLAR (Study of Latino Adolescents at Risk for Diabetes)	Breastfeeding and pre-diabetes		MetS	Ļ
Dugas 2018 <sup>60</sup>	Institute of Nutrition and Functional Foods, Laval University	Breastfeeding		Fasting glucose	n.s.
				Fasting insulin	n.s.
				HbA1c	Ļ
				HOMA-IR	n.s.
Zhang 2017 <sup>94</sup>	Tianjin Gestational Diabetes Mellitus Prevention Program (TGDMPP)		Physical Activity (sedentary behavior)	Hyperglycemia	↑
			Sleeping Time	Hyperglycemia	$\downarrow$
Boney 2005 <sup>102</sup>	Women and their children from Women and Infant's hospital		Birthweight (LGA)	MetS	1
Borgoño 2012 <sup>103</sup>			Weight Gain (1st year)	HOMA-IR	1

Del Gobbo 2012 <sup>104</sup>	N/A	Diet (Mg)		Fasting glucose (in females)	$\downarrow$
Wilk 2015 <sup>105</sup>	N/A		Birthweight	HOMA-IR	1
Maslova 2017 <sup>76</sup>	Danish National Birth Cohort (DNBC)	Diet (protein intake)		HOMA-IR	n.s.
				Fasting insulin	<b>↑</b>
Dugas 2019 <sup>106</sup>	Institute of Nutrition and Functional Foods, Laval University		Diet (HEI-C)	HOMA-IR	Ļ
	-		Overweight	Beta-cell response	↑
				Triglycerides	n.s.
				HDL	n.s.
Kelstrup 2016 <sup>71</sup>	N/A	Gene Expression (Adipose Tissue: PPARGC1A)		HOMA-IR	n.s.
		DNA Methylation + BMI		HOMA-IR	1

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; HEI - healthy eating index; HDL – high density lipoprotein; HOMA-IR – homeostatic model assessment of insulin resistance; HbA1c – hemoglobin A1c; MetS – metabolic syndrome; n.s. - not significant; T2D – type 2 diabetes.

Author Year	Trial Name	Intervention and/or Exposure	Offspring Outcome	Association
Landon 2015 <sup>110</sup>	Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network randomized clinical trial (RCT)	Treatment (dietary intervention, self- monitory of glucose, and insulin therapy) vs. standard of care	Blood pressure	n.s.
			Lipids	n.s.
			HOMA-IR	n.s.
		Offspring sex (male vs. female)	Fasting glucose	$\downarrow$
Grotenfelt 2020 <sup>111</sup>	Finnish Gestational Diabetes Prevention Study (RADIEL)	Lifestyle intervention (counseling of exercise and diet)	Metabolic risk profile	↑
Keely 2008 <sup>112</sup>	RCT at the Ottawa Hospital (General and Civic campuses) and the Children's Hospital of Eastern Ontario, in Ottawa, Canada	Treatment (regular check-ups + dietary counseling) vs. Routine Care	Lipids	1
			HOMA-IR	↑
			Glucose (fasting and 2 hour)	n.s.
Malcolm 2006 <sup>113</sup>	RCT at the Ottawa Hospital (General and Civic campuses) and the Children's Hospital of Eastern Ontario, in Ottawa,	Treatment (regular check-ups and were given dietary counseling) vs.	Fasting glucose n.s.	

**TABLE 8**. Randomized control trials evaluating prognostic factors associated with cardiometabolic outcomes among offspring exposed to GDM *in utero* (n=7).

	Canada	Routine Care		
Wroblewska-Seniuk 2009 <sup>91</sup>	Children born in Clinical Hospital of Obstetrics and Gynecology in Poznan, Poland	Treatment (diet vs. insulin)	Glucose	n.s.
			Insulin	n.s.
			HOMA-IR	n.s.
			HbA1c	n.s.
Egeland 2010 <sup>61</sup>	N/A	Treatment (diet vs. insulin)	Insulin	$\downarrow$
			Glucose	$\downarrow$
			Fasting glucose	n.s.
			Lipids	n.s.
			HOMA-IR	n.s.
Battin 2015 <sup>114</sup>	MiG Trial	Treatment (diet vs. insulin)	Blood pressure	n.s.

Abbreviations: BMI – body mass index; CRP – C-reactive protein; CVD – cardiovascular disease; GDM – gestational diabetes mellitus; HOMA-IR – homeostatic model assessment of insulin resistance; HbA1c – hemoglobin A1c; : n.s. - not significant; T2D – type 2 diabetes.



